Murilo Luz

2.0k total citations · 2 hit papers
34 papers, 1.1k citations indexed

About

Murilo Luz is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Murilo Luz has authored 34 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 11 papers in Radiology, Nuclear Medicine and Imaging and 9 papers in Oncology. Recurrent topics in Murilo Luz's work include Prostate Cancer Treatment and Research (21 papers), Radiopharmaceutical Chemistry and Applications (11 papers) and Cancer, Lipids, and Metabolism (8 papers). Murilo Luz is often cited by papers focused on Prostate Cancer Treatment and Research (21 papers), Radiopharmaceutical Chemistry and Applications (11 papers) and Cancer, Lipids, and Metabolism (8 papers). Murilo Luz collaborates with scholars based in Brazil, United States and France. Murilo Luz's co-authors include Neal D. Shore, Teuvo L.J. Tammela, Mindaugas Jievaltas, B. Yа. Alekseev, Egils Vjaters, Albertas Ulys, Toni Sarapohja, Karim Fizazi, S. Polyakov and Amir Snapir and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Murilo Luz

27 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

2019 579 citations Karim Fizazi, Neal D. Shore et al. New England Journal of Medicine profile →
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer

2023 114 citations Stephen J. Freedland, Murilo Luz et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Murilo Luz Brazil	7	952	324	303	199	175	34	1.1k
S. Polyakov Belarus	8	811 0.9×	281 0.9×	273 0.9×	180 0.9×	153 0.9×	20	940
Iris Kuss Germany	12	1.1k 1.2×	400 1.2×	400 1.3×	251 1.3×	224 1.3×	40	1.3k
Per Rathenborg Denmark	11	923 1.0×	325 1.0×	308 1.0×	309 1.6×	182 1.0×	18	1.1k
Sharon McCarthy United States	8	962 1.0×	326 1.0×	341 1.1×	217 1.1×	175 1.0×	28	1.1k
Albertas Ulys Lithuania	16	1.1k 1.2×	459 1.4×	337 1.1×	323 1.6×	235 1.3×	64	1.4k
Vahid Naini United States	8	1.1k 1.1×	357 1.1×	417 1.4×	244 1.2×	191 1.1×	21	1.2k
Álvaro Juárez Soto Spain	8	1.1k 1.1×	345 1.1×	379 1.3×	222 1.1×	201 1.1×	44	1.2k
Julia Shelkey United States	6	821 0.9×	303 0.9×	246 0.8×	190 1.0×	194 1.1×	9	956
Giri Sulur United States	8	587 0.6×	199 0.6×	216 0.7×	159 0.8×	189 1.1×	19	796
S. Chowdhury United Kingdom	16	699 0.7×	291 0.9×	242 0.8×	267 1.3×	91 0.5×	58	951

Countries citing papers authored by Murilo Luz

Since Specialization

Citations

This map shows the geographic impact of Murilo Luz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Murilo Luz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Murilo Luz more than expected).

Fields of papers citing papers by Murilo Luz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Murilo Luz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Murilo Luz. The network helps show where Murilo Luz may publish in the future.

Co-authorship network of co-authors of Murilo Luz

This figure shows the co-authorship network connecting the top 25 collaborators of Murilo Luz. A scholar is included among the top collaborators of Murilo Luz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Murilo Luz. Murilo Luz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maluf, Fernando Cotait, Karine Martins da Trindade, Daniel D’Almeida Preto, et al.. (2025). Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Advanced Penile Cancer. JAMA Oncology. 11(11). 1314–1314.

Luz, Murilo, Letusa Albrecht, Mateus Nóbrega Aoki, et al.. (2025). Comparative Analysis of Cytokine Expression Profiles in Prostate Cancer Patients. Biology. 14(5). 505–505.

Joshi, Himanshu, et al.. (2025). Predicting side-specific extraprostatic extension in prostate cancer using an 18F-DCFPyL PSMA-PET/CT–based nomogram. Prostate Cancer and Prostatic Diseases. 29(1). 124–131.

Cerci, Juliano J., Stefano Fanti, Rakesh Kumar, et al.. (2025). ⁶⁸ Ga-PSMA-11 in Staging of Unfavorable Intermediate- and High-Risk Prostate Cancer Reduces Indication for Noncurative Prostatectomy: A Prospective, Multicenter, IAEA Study. Journal of Nuclear Medicine. 67(1). 67–70.

Shore, Neal D., Murilo Luz, Ugo De Giorgi, et al.. (2025). Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 394(6). 563–575. 1 indexed citations

Cerci, Juliano J., et al.. (2024). PSMA PET/CT in the Brazilian Unified Healthcare System reduces costs with futile salvage therapies in the management of cases of biochemical recurrence of prostate cancer. Radiologia Brasileira. 57. e20240024–e20240024. 1 indexed citations

Bourlon, María T., Laurence Albigès, Matías Chacón, et al.. (2024). Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial.. Journal of Clinical Oncology. 42(16_suppl). 4532–4532. 2 indexed citations

Yu, Evan Y., Christopher Pieczonka, Hiroyoshi Suzuki, et al.. (2023). Darolutamide observational (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: Second interim analysis.. Journal of Clinical Oncology. 41(16_suppl). e17095–e17095. 1 indexed citations

Freedland, Stephen J., Murilo Luz, Ugo De Giorgi, et al.. (2023). Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. New England Journal of Medicine. 389(16). 1453–1465. 114 indexed citations breakdown →

10.

Shore, Neal D., Karim Fizazi, Teuvo L.J. Tammela, et al.. (2023). Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study. European Journal of Cancer. 195. 113342–113342.

11.

Shore, Neal D., Murilo Luz, Albertas Ulys, et al.. (2023). Long-term safety and tolerability of darolutamide and duration of treatment in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the ARAMIS Rollover Study.. Journal of Clinical Oncology. 41(6_suppl). 147–147. 3 indexed citations

12.

Maluf, Fernando Cotait, Karine Martins da Trindade, Daniel D’Almeida Preto, et al.. (2023). A phase II trial of pembrolizumab combined with platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.. Journal of Clinical Oncology. 41(6_suppl). TPS14–TPS14. 4 indexed citations

13.

Fontes, Mariane, et al.. (2022). Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System Database. World Journal of Oncology. 13(6). 350–358.

14.

Bögemann, Martin, Neal D. Shore, Matthew R. Smith, et al.. (2022). Efficacy and Safety of Darolutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer Stratified by Prostate-specific Antigen Doubling Time: Planned Subgroup Analysis of the Phase 3 ARAMIS Trial. European Urology. 83(3). 212–221. 7 indexed citations

15.

Shore, Neal D., Karim Fizazi, Teuvo L.J. Tammela, et al.. (2021). Analysis of the effect of crossover from placebo (PBO) to darolutamide (DARO) on overall survival (OS) benefit in the ARAMIS Trial.. Journal of Clinical Oncology. 39(6_suppl). 240–240. 1 indexed citations

16.

Smith, Matthew R., Neal D. Shore, Teuvo L.J. Tammela, et al.. (2021). Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. European Journal of Cancer. 154. 138–146. 23 indexed citations

17.

Fizazi, Karim, Neal D. Shore, Teuvo L.J. Tammela, et al.. (2020). 223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). Annals of Oncology. 31. S1328–S1328. 2 indexed citations

18.

Luz, Murilo, et al.. (2015). Adjuvant radiotherapy versus observation alone, after radical prostatectomy in high risk prostate cancer. Revista da Associação Médica Brasileira. 61(4). 324–328. 1 indexed citations

19.

Luz, Murilo, et al.. (2014). Laparoscopic partial nephrectomy for renal cell carcinoma in a horseshoe kidney. Canadian Urological Association Journal. 8(11-12). 918–918. 18 indexed citations

20.

Luz, Murilo, et al.. (2014). Peritoneal metastases from renal cell carcinoma: Images in urology. Canadian Urological Association Journal. 8(5-6). 391–391. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact